RBC Comments on Vertex (VRTX) Following Orkambi Briefing Docs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to RBC Comments on Vertex (VRTX) Following Orkambi Briefing Docs

UPDATE: Vertex Pharma's (VRTX) Orkamibi Recommended for Approval by FDA Panel

May 12, 2015 3:42 PM EDT

(Updated - May 12, 2015 3:46 PM EDT)

Vertex Pharma (NASDAQ: VRTX) Orkamibi Recommended for Approval by FDA Panel. According to Bloomberg, the panel vote was 12-1.

Previously, the FDA panel said Orkambi is safe to treat cystic fibrosis and that it couldn't determine if Lumacaftor contributes positively to Orkambi combo.

... More

Vertex Pharma (VRTX) Shares Halted Ahead of FDA Advisory Committee Meeting

May 12, 2015 7:31 AM EDT

Vertex Pharma (NASDAQ: VRTX) shares were halted for news ahead of an FDA advisory committee meeting on Orkambi.

... More

Vertex (VRTX) Orkambi Briefing Docs 'Positive Overall', Baird Says

May 8, 2015 12:29 PM EDT

Baird analyst Brian Skorney weighed in on Outperform-rated Vertex (NASDAQ: VRTX) after the FDA briefing docs on Orkambi. While not benign he said they look positive overall.

"The FDA review of the lumacaftor/ivacaftor combo didn't yield any smoking gun and generally... More

Vertex Pharma (VRTX) on Watch After FDA Posts Briefing Docs for Orkambi to Treat CF

May 8, 2015 8:03 AM EDT

The FDA posted briefing docs related to Vertex Pharma's (NASDAQ: VRTX) lumacaftor/ivacaftor (Orkambi) combination oral tablets for the treatment of cystic fibrosis.

... More